Citigroup’s Juno Therapeutics, Inc. JUNO Stock Holding History

Citigroup’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-83,438	Closed	-$3.81M	–	7814
2017 Q4	$3.81M	Buy	83,438 +44,508	+114%	+$2.22M	﹤0.01%	2095
2017 Q3	$1.75M	Sell	38,930 -47,119	-55%	-$1.61M	﹤0.01%	2803
2017 Q2	$2.57M	Sell	86,049 -1,347	-2%	-$33.2K	﹤0.01%	2339
2017 Q1	$1.94M	Sell	87,396 -169,544	-66%	-$3.64M	﹤0.01%	2525
2016 Q4	$4.84M	Buy	256,940 +240,000	+1,417%	+$5.87M	﹤0.01%	1874
2016 Q3	$508K	Sell	16,940 -12,924	-43%	-$402K	﹤0.01%	3882
2016 Q2	$1.15M	Buy	29,864 +20,893	+233%	+$867K	﹤0.01%	2818
2016 Q1	$342K	Sell	8,971 -62,918	-88%	-$2.19M	﹤0.01%	4561
2015 Q4	$3.16M	Sell	71,889 -20,161	-22%	-$1,000K	﹤0.01%	2110
2015 Q3	$3.75M	Buy	92,050 +44,077	+92%	+$1.93M	﹤0.01%	1906
2015 Q2	$2.56M	Buy	47,973 +41,473	+638%	+$2.2M	﹤0.01%	2302
2015 Q1	$394K	Buy	+6,500	New	+$315K	﹤0.01%	3964

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citigroup's JUNO Position: Q1 2018 in Review

Citigroup sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 83,438 shares — an estimated $3.81M sold.

Citigroup first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $4.84M in Q4 2016. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Citigroup reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Citigroup sold 83,438 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.81M.
Citigroup first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
Citigroup's Juno Therapeutics, Inc. position peaked at $4.84M in Q4 2016.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Citigroup's 13F filing for Q1 2018, filed 11 May 2018.